BlackRock
GPCR icon

BlackRock’s Structure Therapeutics GPCR Stock Holding History

BlackRock’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4M Buy
511,149
+69,174
+16% +$3.06M ﹤0.01% 3061
2026
Q1 		$21.3M Buy
441,975
+11,893
+3% +$814K ﹤0.01% 3048
2025
Q4 		$29.9M Buy
430,082
+166,144
+63% +$6.78M ﹤0.01% 2845
2025
Q3 		$7.39M Buy
263,938
+20,604
+8% +$410K ﹤0.01% 3606
2025
Q2 		$5.05M Sell
243,334
-323,171
-57% -$7.11M ﹤0.01% 3771
2025
Q1 		$9.81M Sell
566,505
-44,080
-7% -$1.08M ﹤0.01% 3331
2024
Q4 		$16.6M Sell
610,585
-69,512
-10% -$2.47M ﹤0.01% 3159
2024
Q3 		$29.8M Sell
680,097
-262,922
-28% -$10.2M ﹤0.01% 2788
2024
Q2 		$37M Sell
943,019
-143,394
-13% -$5.89M ﹤0.01% 2590
2024
Q1 		$46.6M Buy
1,086,413
+25,355
+2% +$1.07M ﹤0.01% 2471
2023
Q4 		$43.2M Buy
1,061,058
+533,728
+101% +$30.6M ﹤0.01% 2560
2023
Q3 		$26.6M Buy
527,330
+132,484
+34% +$4.27M ﹤0.01% 2776
2023
Q2 		$16.4M Sell
394,846
-5,154
-1% -$144K ﹤0.01% 3152
2023
Q1 		$9.52M Buy
+400,000
New +$9.4M ﹤0.01% 3343

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BlackRock's GPCR Position: Q2 2026 in Review

BlackRock increased its Structure Therapeutics (GPCR) stake by 16% in Q2 2026, buying an estimated $3.06M and bringing the position to 511,149 shares worth $27.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3061.

BlackRock first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $46.6M in Q1 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • BlackRock held 511,149 shares of Structure Therapeutics worth $27.4M as of Q2 2026.
  • BlackRock bought 69,174 Structure Therapeutics shares in Q2 2026, an estimated $3.06M.
  • Structure Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3061 holding.
  • BlackRock first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • BlackRock's Structure Therapeutics position peaked at $46.6M in Q1 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.